Plus therapeutics announces selection of “rhenium (186re) obisbemeda” as international non-proprietary name for 186rnl

Austin, texas, oct. 26, 2022 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the world health organization's (who) international non-proprietary name (inn) expert committee has selected the non-proprietary name “rhenium (186re) obisbemeda” for the company's lead investigational targeted radiotherapeutic, formerly known as 186rnl. going forward, plus therapeutics will use rhenium (186re) obisbemeda in place of 186rnl.
PSTV Ratings Summary
PSTV Quant Ranking